安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CAR 安飞士

休市中 10-16 16:00:00 EDT

102.83

-6.94

-6.32%

盘后102.70

-0.13-0.13%

19:52 EDT

最高112.49	最低102.05	成交量34.58万
今开109.85	昨收109.77	日振幅9.51%
总市值36.32亿	流通市值15.27亿	总股本3,532万
成交额3,614万	换手率2.33%	流通股本1,485万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CAR","market":"US","secType":"STK","nameCN":"安飞士","latestPrice":102.83,"timestamp":1792180800000,"preClose":109.77,"halted":0,"volume":345751,"hourTrading":{"tag":"盘后","latestPrice":102.7014,"preClose":102.83,"latestTime":"19:52 EDT","volume":11915,"amount":1225377.08,"timestamp":1792194778389,"change":-0.1286,"changeRate":-0.001251,"amplitude":0.003793},"delay":0,"changeRate":-0.06322310285141658,"floatShares":14852200,"shares":35324685,"eps":-17.940762,"marketStatus":"休市中","change":-6.94,"latestTime":"10-16 16:00:00 EDT","open":109.85,"high":112.485,"low":102.05,"amount":36139768.49042,"amplitude":0.095062,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-17.940762,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":109.77,"preHourTrading":{"tag":"盘前","latestPrice":110.86,"preClose":109.77,"latestTime":"08:14 EDT","volume":41,"amount":4547.696466,"timestamp":1792152854170,"change":1.09,"changeRate":0.00993,"amplitude":0.001919},"postHourTrading":{"tag":"盘后","latestPrice":102.7014,"preClose":102.83,"latestTime":"19:52 EDT","volume":11915,"amount":1225377.08,"timestamp":1792194778389,"change":-0.1286,"changeRate":-0.001251,"amplitude":0.003793},"volumeRatio":1.0789303535271308,"impliedVol":0.7507,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/CAR","defaultTab":"news","newsList":[{"id":"2671622332","title":"《自然》：下一代CAR-T在研药物，82%由中国团队主导","url":"https://stock-news.laohu8.com/highlight/detail?id=2671622332","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671622332?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:33","pubTimestamp":1790724822,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663046879","title":"礼来上半年营收427.73亿美元，替尔泊肽占比65%近277亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663046879","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663046879?lang=zh_cn&edition=full","pubTime":"2026-08-30 12:16","pubTimestamp":1788063391,"startTime":"0","endTime":"0","summary":"近日，礼来（EliLillyandCompany，NYSE：LLY）公布2026年上半年及第二季度业绩。财报显示，今年上半年，礼来实现总营收427.73亿美元，同比增长49%。其中第二季度营收达229.74亿美元，同比增长48%，超市场预期。基于上半年的强劲增长势头，礼来将2026年全年营收指引从此前的820亿至850亿美元上调至850亿至870亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859354883.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859354883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0326950275.SGD","01801","BK1589","HK0000165453.HKD","CAR","LU2097828714.EUR","ADC","LU1969619763.USD","LU0463099449.HKD","BK1161","LU2242644610.SGD","LU2097828474.EUR","LU2097828631.EUR","NETL","LU2097828805.USD","BK4080","LU0244354667.USD","LU2097828557.USD","LU0455707207.USD","LU2488822045.USD","KURE","BK1583","LU0502904849.HKD","BK4230","BK4022","LU2328871848.SGD","LU1188198961.HKD","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662105790","title":"惠正奇医药创始人回爱民：mRNA癌症疫苗大规模应用仍需3-5年，不会取代CAR-T或PD-1/PD-L1疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2662105790","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662105790?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:30","pubTimestamp":1787740212,"startTime":"0","endTime":"0","summary":"如果后续获得监管批准，它将成为全球首个上市的mRNA肿瘤疫苗，开启个体化肿瘤疫苗治疗的新时代。回爱民：我认为，mRNA个性化癌症疫苗不会简单取代CAR-T或PD-1/PD-L1疗法，而是会带来差异化竞争和新的联合模式。因此，mRNA疫苗对PD-1/PD-L1疗法的影响主要是协同增效。intismeran取得阳性结果的方案本身就是与帕博利珠单抗联合，说明个性化疫苗未来更可能扩大PD-1/PD-L1疗法的获益人群，而不是取代它。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787738561624097620","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1169590202.USD","BK4022","CAR","BK1515","LU1169589451.USD","BK4023","159646","PD","BK1574","09939","BK1161","BK4230","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431074","title":"全球首款实体瘤CAR-T卖99万元，科济药业称销售额在下半年确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431074","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431074?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:08","pubTimestamp":1787126930,"startTime":"0","endTime":"0","summary":"今年6月22日，科济药业（02171.HK）的恺力美作为全球首款治疗实体瘤的CAR-T细胞产品获批国内上市，用于晚期胃癌治疗，但售价高达99万元，究竟会有多少患者愿意买单？随着公司半年报披露，该问题受到投资者关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608193846256878.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608193846256878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","CAR","BK4230","BK4022","BK1161","BK1585","BK1574","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659206134","title":"虹信生物宣布完成数亿元B轮融资 |【经纬低调新闻】","url":"https://stock-news.laohu8.com/highlight/detail?id=2659206134","media":"经纬创投","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659206134?lang=zh_cn&edition=full","pubTime":"2026-08-13 12:18","pubTimestamp":1786594680,"startTime":"0","endTime":"0","summary":"综述近日，深圳虹信生物科技有限公司宣布完成B轮融资，老股东经纬创投跟投，合计融资金额数亿元人民币。经纬观点2025年，经纬创投投资了虹信生物的A轮融资，并在本轮继续跟投。融资新闻虹信生物成立于2021年12月，致力于开发基于体内LNP-mRNA细胞靶向递送技术的先进免疫疗法。基于该平台，虹信生物开发的In vivo CAR-T管线HN2301已于2025年一季度完成了首例SLE病人的给药，为细胞靶向LNP在全球范围内首次进入人体临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962188413&idx=2&sn=87b9f8edb6d780e989a884fd8d0c5c39&chksm=ab7d29d64d0ca345d0f81c2b7b0349d390f07c163c544a04496c89002276da7a0419cacfc1ec&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4110","CAR","BK4022","BK4230","ACR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655495768","title":"强生(JNJ.US)持续加码创新疗法：携手Sail开发体内CAR-T并获得25.8亿美元收购选择权 完成收购Firefly Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2655495768","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655495768?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:52","pubTimestamp":1785376375,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IYH","LU0203345920.USD","LU0122379950.USD","LU0058720904.USD","LU1496350502.SGD","LU1057294990.SGD","IE00BKVL7J92.USD","LU2347655156.SGD","LU0234570918.USD","LU2129689514.USD","TRUH","LU0289739699.SGD","LU1032466523.USD","LU1228905037.USD","IE00B2B36J28.USD","RXL","IHE","PJP","LU0683600562.USD","LU1059921491.USD","IE00BN8TJ469.HKD","JDOC","LU2471134796.USD","IE000SO60NU8.SGD","LU0124676726.USD","XLV","FTXH","LU0098860793.USD","GDOC","LU1043141396.HKD","VHT","IXJ","FHLC","IE0001KFT4U8.USD","BK4592","BK4533","BMED","JNJ","LU1718418525.SGD","IE000MB6IJN5.SGD","LU1066053197.SGD","LU1894683348.USD","LU2112291526.USD","BK4534","CAR","LU2468319806.SGD","IE00BSNM7G36.USD","LU0432979614.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655560865","title":"安飞士（CAR）盘前跌12.28% 营收同比下滑1.3%至30亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655560865","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655560865?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:43","pubTimestamp":1785318196,"startTime":"0","endTime":"0","summary":"金吾财讯 | 安飞士（CAR）盘前震荡走低，盘前报145.890美元，盘前下跌12.28%。消息层面上，这家汽车租赁公司第二季度营收和盈利未达预期，尽管盈利能力显著改善且车队利用率创纪录，股价仍大幅下挫。营收同比下滑1.3%至30亿美元；每股收益为0.98美元，低于预期，盖过了车辆利用率创纪录达到72.6%、车队成本下降以及与Waymo自动驾驶汽车合作取得进展等利好。投资者也仍对持续的旅行需求逆风以及网约车对租车预订的影响保持谨慎。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303151","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655570498","title":"美股异动丨安飞士盘前大跌逾15% 业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655570498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655570498?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:16","pubTimestamp":1785312964,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4230","BK4022","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654401032","title":"科济全球首款实体瘤CAR-T获批之后 李宗海谈创新药可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2654401032","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654401032?lang=zh_cn&edition=full","pubTime":"2026-07-25 04:10","pubTimestamp":1784923816,"startTime":"0","endTime":"0","summary":"99万定价，全球首款实体瘤CAR-T细胞疗法在中国获批。一个月前，科济药业（2171.HK）自主研发的舒瑞基奥仑赛注射液获国家药监局批准上市，这是全球首款获批用于实体瘤治疗的CAR-T细胞治疗产品。7月15日下午1点20分，科济药业位于上海徐汇区办公地址四楼的实验室大门被缓缓推开，公司创始人、董事长李宗海博士走了进来。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607253820887995.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607253820887995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159992","BK4022","BK4230","MEDX","IBBQ","LNGR","BK1161","06978","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653696077","title":"HERO CAR就位，新一代理想L6要做体验之王","url":"https://stock-news.laohu8.com/highlight/detail?id=2653696077","media":"亿欧网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653696077?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:01","pubTimestamp":1784728860,"startTime":"0","endTime":"0","summary":"正是在长期注重用户体验的基础上，7月16日，新一代理想L6正式发布，全国统一零售价24.98万元。现在，作为曾经的HERO CAR，李想有信心让新一代L6成为体验之王，绝非空中楼阁，其背后是一系列成熟技术的全面托举。目前，理想L6以“HERO CAR”的姿态，累计销量一举突破40万辆，这一数据不仅刷新了细分市场的纪录，更使其登顶中国累计销量最高的中大型SUV宝座。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-22/doc-iniisxzw7950633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4022","BK4230","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190128822","title":"财报前瞻｜安飞士本季度营收预计增3.11%，机构更偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1190128822","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190128822?lang=zh_cn&edition=full","pubTime":"2026-07-21 11:19","pubTimestamp":1784603988,"startTime":"0","endTime":"0","summary":"安飞士将于2026年07月28日发布新一季财报，市场关注成本结构与盈利修复路径。市场一致预期安飞士本季度营收为31.01亿美元，同比增长3.11%；调整后每股收益为1.67美元，同比下降9.96%；息税前利润为2.86亿美元，同比增长67.36%，若无更多信息披露，毛利率与净利率预测暂缺。针对安飞士即将发布的新季财报，综合近期机构评述，持谨慎观点的比例更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜安飞士本季度营收预计增3.11%，机构更偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653240168","title":"WAIC 2026｜AI+量子切入百亿美元体内CAR-T市场：英硅智能参投元码智药，并携手沙丘量子达成三方合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653240168","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653240168?lang=zh_cn&edition=full","pubTime":"2026-07-21 08:30","pubTimestamp":1784593800,"startTime":"0","endTime":"0","summary":"值得一提的是，英硅智能于近期以战略投资人身份参与元码智药数千万元Pre-A轮融资，募集资金拟用于元码智药体内CAR-T和肿瘤疫苗管线临床推进与开发，以及与英硅智能协同共建下一代AI原生mRNA药物研发引擎。英硅智能的战略投资以及本次三方合作，代表行业领军者对元码智药技术路径与创新能力的持续信任。自 2021 年以来，公司已提名 31 个临床前候选化合物，其中 13 个已获得 IND 批件。迄今为止，Human Longevity 和 Liquid AI 已与英硅智能达成合作，成为 MMAI Gym 的合作伙伴。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5007825_ZH07825_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5007825_ZH07825_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CAR","CHAT","AIPO","BK1141","VTHR","AGIX","BK4230","QTOC","03696","ARTY","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491248","title":"传奇生物CAR-T疗法第二季度产生贸易销售净额约6.57亿美元；天智航筹划购买上海骨科控股权 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491248","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651491248?lang=zh_cn&edition=full","pubTime":"2026-07-16 07:04","pubTimestamp":1784156682,"startTime":"0","endTime":"0","summary":"丨2026年7月16日星期四丨NO.1天智航筹划发行股份购买上海骨科的控股权并募集配套资金7月15日，天智航公告称，公司正在筹划以发行股份的方式购买上海微创骨科医疗科技有限公司（简称“上海骨科”）的控股权，同时拟募集配套资金。根据上海证券交易所相关规定，经公司申请，公司股票将于2026年7月16日（星期四）开市起停牌，预计停牌时间不超过5个交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163807947018.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163807947018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LEGN","MEDI","BK4588","159938","BK4585","BK4139","BK1515","MEMS","09939","BK1161","BK1574","CANC","CAR","BK4022","BK4230","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111689","title":"国内首批！仁济医院开展实体瘤CAR-T治疗，改写晚期胃癌患者治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111689","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651111689?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:12","pubTimestamp":1783944744,"startTime":"0","endTime":"0","summary":"近日，上海交通大学医学院附属仁济医院肿瘤科主任肖秀英及其团队完成2例实体瘤CAR-T细胞采集工作，这标志着国际前沿实体瘤细胞治疗技术在该院实现规范化临床落地，符合治疗指征的晚期胃癌患者可通过标准化诊疗路径接受舒瑞基奥仑赛注射液（CT041）治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607133804038612.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607133804038612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4230","BK4022","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109538878","title":"异动解读｜安飞士盘中上涨5.01%，租车板块集体反弹叠加再融资利好支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1109538878","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109538878?lang=zh_cn&edition=full","pubTime":"2026-07-10 00:30","pubTimestamp":1783614600,"startTime":"0","endTime":"0","summary":"7月9日，安飞士盘中上涨5.01%，报160.86美元/股，成交额1507.19万美元。消息面上，公司近期完成20亿美元循环贷款再融资，新贷款期限延长至2031年，同时新设2亿美元循环信贷额度至2028年到期，优化了资本结构并增强财务灵活性。此外，公司此前与Pentwater资本管理达成6.5亿美元现金和解协议，消除诉讼不确定性。当前租车板块整体走强，同业赫兹租车涨7.36%，板块前期因二手车市场降温超跌后迎来修复反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159666159","title":"安飞士预算集团于2026年6月29日签订信贷协议第十一次修正案 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1159666159","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159666159?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:39","pubTimestamp":1783413568,"startTime":"0","endTime":"0","summary":"安飞士预算集团已采取重要财务举措。根据提交给美国证券交易委员会的文件，该公司于2026年6月29日，对其信贷协议进行了第十一次修订。\n此次修订的核心内容涉及大规模债务重组。公司对其原有的20亿美元循环贷款额度进行了再融资，取而代之的是一笔新的、等额的循环贷款安排。这笔新融资的到期日定于2031年6月29日，为公司提供了更长的资金使用期限。\n此外，安飞士预算集团还建立了另一项独立的融资渠道。公司新设立了一笔价值2亿美元的循环贷款额度，该额度将于2028年6月29日到期。这一系列行动旨在优化公司的资本结构，增强财务灵活性，并为未来的运营和发展提供稳定的资金支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4230","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190790567","title":"异动解读｜安飞士盘中下跌5.04%，租车板块持续承压回吐前期涨幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1190790567","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190790567?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:35","pubTimestamp":1783348551,"startTime":"0","endTime":"0","summary":"7月6日，安飞士盘中下跌5.04%，报155.2美元/股，成交额1447.68万美元。消息面上，同业赫兹此前因二手车交易市场降温下调二季度业绩预期，5月车辆处置出现账面亏损，拖累单车月度净折旧指标，板块估值持续承压。安飞士此前于7月初完成20亿美元循环贷款再融资后股价一度大幅反弹逾11%，当前回落或系前期急涨后的获利回吐与行业基本面疲软共振所致。旅客陆运板块整体偏弱，优步跌2.49%，Grab跌5.77%，赫兹租车跌1.65%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649115876","title":"全球首款实体瘤CAR-T上市3天即落地临床，在沪完成首例患者细胞采集","url":"https://stock-news.laohu8.com/highlight/detail?id=2649115876","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649115876?lang=zh_cn&edition=full","pubTime":"2026-07-06 06:00","pubTimestamp":1783288814,"startTime":"0","endTime":"0","summary":"全球首款实体瘤CAR-T产品舒瑞基奥仑赛注射液正式获批上市仅3天后，首例商业化实体瘤CAR-T患者细胞采集在复旦大学附属中山医院顺利完成。这一临床实践标志着实体瘤CAR-T治疗正式迈入商业化临床应用阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607063794358935.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607063794358935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4022","BK4230","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649131916","title":"专访科济药业李宗海：“造出全球首个实体瘤CAR-T产品后，我决定不再布局自体型新管线”","url":"https://stock-news.laohu8.com/highlight/detail?id=2649131916","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649131916?lang=zh_cn&edition=full","pubTime":"2026-07-05 19:42","pubTimestamp":1783251770,"startTime":"0","endTime":"0","summary":"6月25日，科济药业联合创始人、董事会主席、首席执行官兼首席科学官李宗海在北京参加细胞治疗行业论坛，当天下午，科济药业是全场焦点。3天前，这家中国公司拿下全球首款针对实体瘤的CAR-T（嵌合抗原受体T细胞免疫疗法）细胞治疗产品。身为公司灵魂人物的李宗海，成为会场最忙碌的“被围者”。面对持续不断的添加微信好友的申请，他和往常一样几乎照单全收，“（如果）摆个架子多不好意思”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607053794290285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607053794290285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4022","BK1161","BK1574","CAR","02171","BK1585","BK4230","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696037","title":"距获批上市仅3天，全国首例商业化实体瘤CAR-T患者细胞采集完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696037","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648696037?lang=zh_cn&edition=full","pubTime":"2026-07-04 16:51","pubTimestamp":1783155083,"startTime":"0","endTime":"0","summary":"记者今天获悉，复旦大学附属中山医院肿瘤内科刘天舒教授团队6月25日顺利完成全国首例商业化实体瘤CAR-T患者细胞采集。距离舒瑞基奥仑赛注射液正式获批上市仅3天，这一临床实践标志着我国实体瘤CAR-T治疗正式进入商业化应用阶段，也体现了创新治疗成果向临床快速转化的能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607043794190494.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607043794190494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4022","CAR","BK4230","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avisbudgetgroup.com","stockEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":-0.1208},{"period":"3month","weight":-0.3596},{"period":"6month","weight":-0.7918},{"period":"1year","weight":-0.3199},{"period":"ytd","weight":-0.1986}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avis Budget Group, Inc.成立于1946年，是一家全球领先的车辆租赁和汽车共享服务提供商，通过Avis、Budget和Zipcar运营着业内最受认可的三个品牌。该公司是北美、欧洲、澳大利亚、新西兰和某些地区领先的车辆租赁运营商。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.011725},{"month":2,"riseRate":0.5625,"avgChangeRate":0.031733},{"month":3,"riseRate":0.625,"avgChangeRate":0.065494},{"month":4,"riseRate":0.6875,"avgChangeRate":0.039277},{"month":5,"riseRate":0.4375,"avgChangeRate":0.012213},{"month":6,"riseRate":0.5,"avgChangeRate":0.021383},{"month":7,"riseRate":0.5625,"avgChangeRate":0.033163},{"month":8,"riseRate":0.4375,"avgChangeRate":-0.004589},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.042869},{"month":10,"riseRate":0.625,"avgChangeRate":0.109942},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07647},{"month":12,"riseRate":0.4,"avgChangeRate":-0.047503}],"exchange":"NASDAQ","name":"安飞士","nameEN":"Avis Budget"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安飞士,CAR,安飞士股票,安飞士股票老虎,安飞士股票老虎国际,安飞士行情,安飞士股票行情,安飞士股价,安飞士股市,安飞士股票价格,安飞士股票交易,安飞士股票购买,安飞士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安飞士(CAR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安飞士(CAR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}